1. Home
  2. KG vs NSPR Comparison

KG vs NSPR Comparison

Compare KG & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KG

Kestrel Group Ltd.

N/A

Current Price

$9.53

Market Cap

87.3M

Sector

Finance

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.10

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KG
NSPR
Founded
N/A
2005
Country
Bermuda
United States
Employees
44
N/A
Industry
Property-Casualty Insurers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.3M
72.1M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
KG
NSPR
Price
$9.53
$1.10
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
10.7K
100.7K
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
N/A
$57.98
Revenue Next Year
N/A
$95.41
P/E Ratio
$1.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.07
$1.04
52 Week High
$35.37
$2.93

Technical Indicators

Market Signals
Indicator
KG
NSPR
Relative Strength Index (RSI) 44.02 23.99
Support Level $9.90 N/A
Resistance Level $10.74 $2.49
Average True Range (ATR) 0.66 0.09
MACD -0.07 -0.00
Stochastic Oscillator 34.81 22.51

Price Performance

Historical Comparison
KG
NSPR

About KG Kestrel Group Ltd.

Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: